GSK clears another flu vaccine, but patients may not be buying

Share this article:
GSK clears another flu vaccine, but patients may not be buying
GSK clears another flu vaccine, but patients may not be buying

GlaxoSmithKline landed another quadrivalent flu vaccine approval. The company announced August 6 that the FDA approved the drug maker's quadrivalent flu vaccine FluLaval for patients ages three and up. The intramuscular vaccine protects against virus subtypes A and B. The company noted in its statement that this approval means the 2013-2014 flu season will be the first one in which vaccines protecting against more than three strains of the virus will be on hand. The FDA approved the intramuscular Fluarix Quadrivalent in 2012. The company also has Fluarix Trivalent and FluLaval Trivalent versions. Flu seasons generally consist of A and B strains of the virus circulating. The Quad vaccines address two forms of the A strain and two of the B.

The announcement would appear to be timely: a recent CVS survey found that 59% of its survey pool considered  getting the flu shot to be a social responsibility, with more than 60% of those surveyed saying they felt susceptible to the flu when they traveled—which, considering the upcoming travel season, should make the vaccine an appealing defense. Further, the latest Centers for Disease Control data indicates that the last flu season, which officially ends September 28, 2013, was a harsh, one, kicking off four weeks earlier than usual. CDC says the elevated rate of infection lasted 15 weeks back-to-back, which is “slightly longer than average,” and that the US  only returned to below-baseline infection rates in March, the first time since December 2012.

Yet the 2012-2013 infection intensity does not appear to have made a major impression. The very same CVS population that equated vaccination with social responsibility, often seems to think getting vaccinated is someone else's duty: just 46% said they were more likely to get the flu shot this season. Two out of five told CVS that news about outbreaks is what prompts them to make an appointment, meaning these patients are pursuing a reactive approach to health.

Centers for Disease control gave GSK the go-ahead begin shipping the 2012 vaccine, Fluarix Quadrivalent, to healthcare providers. GlaxoSmithKline says the government agency ordered over 4 million doses which will be distributed to state and local healthcare providers. GSK forecasts selling up to 10 million doses Fluarix Quadrivalent and 22 to 24 million of influenza vaccines. Glaxo will manufacture and distributed a limited amount of the just-approved quadrivalent vaccine.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...